Conjuntivitis y abordaje oftalmológico en pacientes con COVID-19: revisión sistemática de la literatura

dc.creatorRey-Rodríguez, Diana Valeria
dc.creatorGodín Estrada, Fernando
dc.creatorAcevedo Espitia, Laura Alejandra
dc.creatorAngarita Contreras, Yury Lady
dc.date23 de febrero de 2022
dc.date2 de junio de 2022
dc.date2022-12-05T08:00:00Z
dc.date.accessioned2023-09-07T21:41:29Z
dc.date.available2023-09-07T21:41:29Z
dc.identifierhttps://ciencia.lasalle.edu.co/svo/vol20/iss1/4
dc.identifierhttps://ciencia.lasalle.edu.co/cgi/viewcontent.cgi?article=1496&context=svo
dc.identifierhttps://ciencia.lasalle.edu.co/context/svo/article/1496/viewcontent/articulo_3_salud_visual_ocular_20_1.pdf
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8748899
dc.descriptionEl objetivo del presente estudio es informar la frecuencia y terapéutica utilizada para el tratamiento de los síntomas asociados a conjuntivitis en pacientes confirmados de COVID-19 en la práctica clínica desde la aparición del virus. Como materiales y métodos, se desarrolló un protocolo de revisión sistemática basado en la declaración Prisma. Además, los artículos para revisión fueron identificados con Google Scholar, Medline (Pubmed), Embase y Web of Science. Como resultados, se identificaron 2815 artículos en la búsqueda bibliográfica; y, tras su lectura completa, se seleccionaron 14 que incluían información sobre la frecuencia de síntomas asociados a conjuntivitis en pacientes positivos para COVID-19. 8 reportes de caso, 4 series de caso y 2 estudios transversales fueron analizados, de los cuales 8 (57,14 %) estudios informaron el tratamiento ocular. En conclusión, la frecuencia de conjuntivitis en pacientes positivos de COVID-19 confirmado en la muestra respiratoria y lagrimal, fue de 52/865 (6,01 %), y el compromiso en la córnea se relacionó con queratitis punteada superficial y pseudodendritas solo en 2/865 (0,23 %) pacientes. La experiencia en el abordaje clínico ha tenido lugar con antivirales orales y tópicos (vanciclovir, ganciclovir, ribavirin), lubricantes oculares y antibióticos tópicos (moxifloxacina), con resolución de síntomas y ausencia de complicaciones posteriores.
dc.descriptionThe current study aims to report the frequency and therapy used for treating symptoms associated with conjunctivitis in confirmed COVID-19 patients in clinical practice since the appearance of the virus. As materials and methods, a systematic review protocol was developed based on the Prisma statement. Also, articles for review were identified using Google Scholar, Medline (Pubmed), Embase, and Web of Science. The bibliographic search identified 2815 results. After complete reading, 14 articles were selected since they included information on the frequency of symptoms associated with conjunctivitis in positive patients for COVID-19. 8 case reports, 4 case series, and 2 cross-sectional studies were analyzed, of which 8 (57.14%) studies reported ocular treatment. The frequency of conjunctivitis in confirmed COVID-19-positive patients in respiratory and tear samples was 52/865 (6.01%). In contrast, corneal involvement was related to superficial punctate keratitis and pseudodendrites, only in 2/865 (0.23%) patients. The experience in the clinical approach has been examined with oral and topical antivirals (vanciclovir, ganciclovir, ribavirin), ocular lubricants, and topical antibiotics (moxifloxacin), with the resolution of symptoms and absence of subsequent complications.
dc.formatapplication/pdf
dc.formate0003
dc.languagespa
dc.publisherUniversidad de La Salle. Ediciones Unisalle
dc.relationCoroneo MT. The eye as the discrete but defensible portal of coronavirus infection. Ocul Surf. 2020;19: 176-182. Disponible en: http://dx.doi.org/10.1016/j.jtos.2020.05.011
dc.relationWillcox MDP, Walsh K, Nichols JJ, Morgan PB, Jones LW. The ocular surface, coronaviruses and COVID-19. Clin Exp Optom. 2020;103(4): 1-7. Disponible en: http://dx.doi.org/10.1111/cxo.13088
dc.relationPeng Y, Zhou YH. Is novel coronavirus disease (COVID-19) transmitted through conjunctiva? J Med Virol. 2020;92(9): 19-20. Disponible en: http://dx.doi.org/10.1002/jmv.25753
dc.relationHu Y, Chen T, Liu M, Zhang L, Wang F, Zhao S, et al. Positive detection of SARS-CoV-2 combined HSV1 and HHV6B virus nucleic acid in tear and conjunctival secretions of a non-conjunctivitis COVID-19 patient with obstruction of common lacrimal duct. Acta Ophthamol. 2020;98(8): 1-5. Disponible en: http://dx.doi.org/10.1111/aos.14456
dc.relationKarimi S, Arabi A, Shahraki T, Safi S. Detection of severe acute respiratory syndrome Coronavirus-2 in the tears of patients with Coronavirus disease 2019. Eye. 2020;34: 1220-1223. Disponible en: https://dx.doi.org/10.1038/s41433-020-0965-2
dc.relationGuan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18): 1708-1720. Disponible en: http://dx.doi.org/10.1056/NEJMoa2002032
dc.relationAlmazroa A, Alamri S, Alabdulkader B, Alkozi H, Khan A, et al. Ocular transmission and manifestation for coronavirus disease: a systematic review. Inter Hea. 2022;14(2): 131-121. Disponible en: https://doi.org/10.1093/inthealth/ihab028
dc.relationQu JY, Xie HT, Zhang MC. Evidence of SARSCoV-2 Transmission Through the Ocular Route. Clin Ophthalmol. 2021;15: 687-696. Disponible en: https://doi.org/10.2147/OPTH.S295283
dc.relationMoher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1): 1. Disponible en: https://doi.org/10.1186/2046-4053-4-1
dc.relationCheema M, Aghazadeh H, Nazarali S, Ting A, Hodges J, McFarlane A, et al. Keratoconjunctivitis as the initial medical presentation of the novel coronavirus disease 2019 (COVID-19). Can J Ophthalmol. 2020;55(4): E125-E129. Disponible en: http://dx.doi.org/10.1016/j.jcjo.2020.03.003
dc.relationLoffredo L, Pacella F, Pacella E, Tiscione G, Oliva A, Violi F. Conjunctivitis and COVID-19: A metaanalysis. J Med Virol. 2020;92(9): 1413-1414. Disponible en: http://dx.doi.org/10.1002/jmv.25938
dc.relationUlhaq ZS, Soraya GV. The prevalence of ophthalmic manifestations in COVID-19 and the diagnostic value of ocular tissue/fluid. Graef Arch Clin Exp Ophthalmol. 2020;258(6): 1351-1352. Disponible en: http://dx.doi.org/10.1007/s00417-020-04695-8
dc.relationHamming I, Timens W, Bulthuis MLC, Lely AT, Navis GJ, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203(2): 631-637. Disponible en: http://dx.doi.org/10.1002/path.1570
dc.relationHoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2): p271-280.e8. Disponible en: http://dx.doi.org/10.1016/j.cell.2020.02.052
dc.relationChandra S, Flanagan D, Hingorani M, Lotery A, Sivaprasad S. COVID19 and ophthalmology: a brief summary of the literature. Eye. 2020;34: 1200-1202. Disponible en: http://dx.doi.org/10.1038/s41433-020-0956-3
dc.relationNavel V, Chiambaretta F, Dutheil F. Haemorrhagic conjunctivitis with pseudomembranous related to SARS-CoV-2. Am J Ophthalmol Case Reports. 2020;19: 100735. Disponible en: http://dx.doi.org/10.1016/j.ajoc.2020.100735
dc.relationChen YY, Yen YF, Huang LY, Chou P. Manifestations and Virus Detection in the Ocular Surface of Adult COVID-19 Patients: A Meta-Analysis. J Ophthalmol. 2021;2021: 9997631. Disponible en: http://dx.doi.org/10.1155/2021/9997631
dc.relationWu P, Liang L, Chen CB, Nie SQ. A child confirmed COVID-19 with only symptoms of conjunctivitis and eyelid dermatitis. Graef Arch Clin Exp Ophthalmol. 2020;258: 19-20. Disponible en: http://dx.doi.org/10.1007/s00417-020-04708-6
dc.relationSen M, Honavar SG, Sharma N, Sachdec MS. COVID-19 and Eye. A Review of Ophthalmic Manifestations of COVID-19. Ind Jour Ophthal. 2021;69(3): 488-509. Disponible en: http://dx.doi.org/10.4103/ijo.IJO_297_21
dc.relationKonjevoda S, Canovic S, Pastar Z, Tabain I, Savic V, Barbic L, et al. Ophthalmic manifestations of novel coronaviruses: precautionary measures and diagnostic possibilities. J Glob Health. 2020;10(1): 1-4. Disponible en: http://dx.doi.org/10.7189/JOGH.10.010340
dc.relationConde Y, Puente Gete B, Gil Ibáñez L, Esquivel Benito G, Asencio Duran M, Dabad Moreno JV. Pandemia COVID-19: impacto sobre la tasa de conjuntivitis virales. Arch Soc Esp Oftalmol. 2022;97(2): 63-69. Disponible en: http://dx.10.1016/j.pftal.2021.03.002
dc.rightshttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rightsAcceso abierto
dc.rightshttp://purl.org/coar/access_right/c_abf2
dc.subjectSARSCoV-2
dc.subjectCOVID-19
dc.subjectconjuntivitis
dc.subjectconjuntiva
dc.subjectSARS-CoV-2, COVID-19, conjunctivitis, conjunctiva
dc.titleConjuntivitis y abordaje oftalmológico en pacientes con COVID-19: revisión sistemática de la literatura
dc.typeArtículo de revisión
dc.identifier.doihttps://doi.org/10.19052/sv.vol20.iss1.4
dc.type.coarhttp://purl.org/coar/resource_type/c_dcae04bc
dc.type.redcolhttp://purl.org/redcol/resource_type/ARTREV
dc.type.contentText
dc.type.coarversionVersión publicada
dc.type.coarversionhttp://purl.org/coar/version/c_970fb48d4fbd8a85
dc.identifier.instnameinstname:Universidad de La Salle
dc.identifier.reponamereponame:Ciencia Unisalle
dc.identifier.repo.urlrepourl:https://ciencia.lasalle.edu.co/
dc.relation.ispartofcitationissue1
dc.relation.ispartofcitationvolume20
dc.relation.ispartofjournalCiencia y Tecnología para la Salud Visual y Ocular
dc.title.translatedConjunctivitis and Ophthalmological Approach in Patients with COVID-19: A Systematic Review of the Literature


Este ítem pertenece a la siguiente institución